Hemoglobinopathies and Related DisordersIron Metabolism and DisordersDiabetes, Cardiovascular Risks, and LipoproteinsBlood Pressure and Hypertension StudiesAdipokines, Inflammation, and Metabolic Diseases
We prepare their research opportunity report and reach out personally to introduce you — their contact details stay private.
Their published papers and profiles list institutional contact details.
This profile was built automatically from public publication records and has not yet been claimed by the researcher.
Research opportunities
Study designs adjacent to this body of work — each grounded in the published record and scoped so a trainee could run it.
Claim your researcher profile
This profile was built from your public publication record — claim it to manage it.
How do specific maternal microbiota profiles (gut, oral, or vaginal) during gestation correlate with the development of gestational diabetes mellitus (GDM) and subsequent long-term metabolic health in offspring?
Why this gap exists: While recent reviews [8] confirm GDM alters maternal gut microbiota and neonatal health, and older studies [0] note dysbiosis across maternal sites, the retrieved evidence lacks direct, longitudinal studies correlating specific gestational maternal microbiota profiles with the *long-term* metabolic health of offspring, leaving the core question unresolved.
Microbes in the Moonlight: How the Gut Microbiota Influences Sleep — arXiv preprint, 2025
What are the specific long-term treatment strategies required to mitigate the risk of developing chronic non-communicable diseases in children born to mothers with gestational diabetes mellitus?
Why this gap exists: While the retrieved literature consistently establishes that maternal gestational diabetes mellitus (GDM) increases the long-term risk of cardiometabolic diseases in offspring [1][2][3], it focuses primarily on pathogenesis and risk association rather than defining specific, evidence-based long-term treatment strategies for the children to mitigate these risks.
To what extent do changes in the maternal microbiota (gut, oral, or vaginal) during pregnancy mediate the relationship between maternal perinatal anxiety/depression and the neurodevelopmental outcomes of the offspring?
Why this gap exists: While recent studies confirm associations between maternal mental health and microbiota composition (Abstract 5, 8) and suggest the microbiome-gut-brain axis influences neurodevelopment (Abstract 0, 2), the retrieved evidence does not contain studies that directly test the mediating role of maternal microbiota changes between perinatal anxiety/depression and offspring neurodevelopmental outcomes.
How does the consumption of plant-based proteins, specifically those high in anti-nutritional factors like phytates and trypsin inhibitors, affect mineral bioavailability and growth outcomes in children relying on these proteins as primary staples?
Why this gap exists: While the retrieved papers confirm that anti-nutritional factors like phytates and trypsin inhibitors reduce mineral bioavailability [0, 2], they focus on general adult health or crop improvement [1, 6] and do not provide direct evidence on the specific growth outcomes in children relying on these proteins as primary staples.
How does the longitudinal trajectory of maternal stress and resilience during pregnancy specifically mediate the association between social determinants of health (e.g., socioeconomic status, structural inequality) and infant cognitive or emotional development outcomes?
Why this gap exists: While the retrieved literature confirms associations between socioeconomic disadvantage, maternal stress, and infant neurodevelopment, it does not resolve the specific question of how longitudinal trajectories of maternal stress and resilience mediate these associations, as the studies focus on broad correlations or static measures rather than dynamic mediation pathways.
Chronic stress may disrupt covariant fluctuations of vitamin D and cortisol plasma levels in pregnant sheep during the last trimester: a preliminary report — arXiv preprint, 2019
What are the comparative efficacy and adherence rates of new short-course latent tuberculosis infection (LTBI) regimens versus traditional long-course therapies in high-burden, low-resource settings?
Why this gap exists: While a 2023 network meta-analysis [6] synthesizes general efficacy and adherence data for LTBI regimens, the retrieved evidence lacks direct comparative studies specifically focused on high-burden, low-resource settings, leaving the specific constraints of these environments unresolved.